Clinical Trial Update: Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating the addition of ruxolitinib to standard tyrosine kinase inhibitor therapy for chronic myeloid leukemia in chronic phase with BCR-A…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-12-18